Chipscreen Biosciences
Manufacturing · China · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
Research Institute of Tsinghua Universit...Phone Number
+86 75526957330Website
www.chipscreen.comRevenue
$46.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Chipscreen Biosciences
微芯生物科技股份有限公司 is a pioneer in the field of innovative pharmaceuticals, dedicated to providing affordable and clinically necessary revolutionary mechanism drugs for patients. The company focuses on developing globally innovative drugs with differentiated advantages in areas such as malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral treatments. With a robust pipeline of new molecular entities and a strong emphasis on AI-assisted drug discovery and clinical development, 微芯 aims to meet clinical needs effectively. Their commitment to innovation is reflected in their extensive patent portfolio and ongoing clinical projects.Explore more
Chipscreen Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Chipscreen Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Chipscreen Biosciences is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Chipscreen Biosciences launches new products
Check if Chipscreen Biosciences has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Chipscreen Biosciences recently announced quarterly report
Click to see if Chipscreen Biosciences had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Chipscreen Biosciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at Chipscreen Biosciences
Chipscreen Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Chipscreen Biosciences as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Chipscreen Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Chipscreen Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Chipscreen Biosciences.
Chipscreen Biosciences Tech Stack
A closer look at the technologies used by Chipscreen Biosciences
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Chipscreen Biosciences News & Media
Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards
SHENZHEN, China, Dec. 29, 2025 /PRNewswire/ -- On December 5, 2025, Dr. Lu Xianping, Founder, Chairman of Shenzhen Chipscreen Biosciences Co., Ltd, has been named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards. This recognition honors his outstanding...Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development
SHENZHEN, China, July 31, 2025 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") announced that its wholly owned subsidiary, Chipscreen Biosciences (USA) Ltd., has received Investigational New Drug (IND) approval from the U.S. Food and Drug...The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved
SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ -- On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the "Drug Clinical Trial Approval Notice" approved by the National Medical Products Administration. The company's self-developed original new drug, Chiauranib, combined with PD - (L) 1 monoclonal antibody and standard chemotherapy for the first-line treatment ofChipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted
SHENZHEN, China, Oct. 17, 2024 /PRNewswire/ -- On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company's Investigational New Drug (IND) application for CS231295 tablets, a Class 1 innovative drug for the treatment of tumors. The application has been accepted by the Center for Drug Evaluation of National Medical Products Administration of China (Application Number: CXHL2401105, CXHL2401107, CXHL2401108). Malignant tumo
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Chipscreen Biosciences
Sign Up For FreeTo access detailed company insights
微芯生物科技股份有限公司 is a pioneer in the field of innovative pharmaceuticals, dedicated to providing affordable and clinically necessary revolutionary mechanism drugs for patients. The company focuses on developing globally innovative drugs with differentiated advantages in areas such as malignant tumors, metabolic diseases, autoimmune diseases, central ne... Read More
